Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line Treatment for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer: Initial Results From BEGONIA, a Phase 1b/2 Study

Preliminary results of the basket BEGONIA trial showed that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), paired with the immune checkpoint inhibitor durvalumab, has strong activity in advanced or metastatic triple-negative breast cancer among patients not biomarker-selected for the trial. As a first-line treatment, the combination therapy produced responses in 74% of patients and exhibited a good safety profile, though mild stomatitis was common.